BSX
Boston Scientific Corp
43.90$
-1.7%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -52.7% | +62.0% | +46.7% | -78.3% | +492.3% | -17.9% | +24.0% | -18.4% | +64.0% | +37.2% | +32.0% | |
| – | +6.1% | +6.0% | +3.6% | +5.9% | +13.1% | +11.1% | -2.7% | +3.9% | +5.3% | +6.1% | +7.8% | |
| – | +3.9% | +8.4% | +9.5% | +10.2% | +12.1% | +8.3% | +14.1% | +13.4% | +5.9% | +14.2% | +12.4% | |
| – | -38.5% | -29.0% | +100.0% | -101.6% | – | -34.3% | -51.2% | +310.0% | – | – | – | |
| – | -70.9% | -101.4% | – | -3,372.7% | – | – | -935.7% | – | – | – | – | |
| – | -4.6% | +52.2% | -15.2% | -0.9% | +45.9% | -18.4% | +47.3% | +10.5% | +30.7% | -1.2% | +10.9% | |
| – | +193.4% | -59.4% | +13.9% | +90.2% | +162.4% | -91.8% | +288.6% | +25.9% | +28.0% | +120.9% | -53.6% | |
| – | -100.0% | – | – | +0.0% | +0.0% | +0.0% | +96.4% | +0.0% | -49.1% | -100.0% | – | |
| – | – | -2.6% | -23.4% | +18.8% | +21.8% | -535.0% | – | +23.6% | +33.8% | +26.4% | +22.6% | |
| – | +3.2% | -113.3% | – | +1,042.3% | +98.9% | -135.8% | -83.5% | +0.0% | -97.6% | – | -126.9% | |
| – | – | -115.6% | – | +1,201.8% | +107.6% | -90.1% | -132.4% | +476.8% | – | +36,180.0% | -121.8% | |
| – | -172.4% | – | – | -135.8% | – | – | -87.5% | -702.3% | – | – | – | |
| – | -65.0% | +68.8% | +85.7% | -100.5% | – | -17.7% | +16.3% | -30.5% | +86.3% | +55.3% | +38.3% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.